The Discounted Cash Flow (DCF) valuation of Beam Therapeutics Inc (BEAM) is (1,109.07) USD. With the latest stock price at 21.17 USD, the upside of Beam Therapeutics Inc based on DCF is -5338.9%.
Based on the latest price of 21.17 USD and our DCF valuation, Beam Therapeutics Inc (BEAM) is a sell. selling BEAM stocks now will result in a potential gain of 5338.9%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 7.4% - 9.5% | 8.5% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (1,937.96) - (803.33) | (1,109.07) |
| Upside | -9254.3% - -3894.7% | -5338.9% |